Baxter International BAX
equity
Price History
The shaded fan is where this price has historically travelled over the months after a close like today’s. It is not a forecast: it has no view on direction, only on distance.
Over 3 months from Sep 2026, roughly two-thirds of past moves landed between $18.83 and $27.61; nine in ten between $16.64 and $31.24.
Tested against this asset’s own history: across 486 past 3-month windows, the price actually landed inside the two-thirds band 71% of the time. The gap from 68% is the model’s error — real returns have fatter tails than the maths assumes, so the band gets breached more often than it claims.
Time underwater
How far below its previous all-time high the price sat, each month. 0% means a new high.
Worst drawdown: −81%, peaking May 2020 and bottoming Mar 2026 — still unrecovered after 76 months.
DCA Backtest
- Invested
- $50,100
- Value today
- $81,724
- Return
- +63.1%
- Months invested
- 501
Scenarios
Inflation — the same contributions merely keeping pace with CPI would be $91,370 today, so the real (inflation-adjusted) return is -10.6%.
Lump sum instead — $50,100 all at once in Jan 1985: $306,172 (+511.1%) — lump sum came out ahead.
Worst timing — same monthly amount started at the all-time high (May 2020): $4,503 on $7,700 invested (-41.5%).
⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.
If this saved you a spreadsheet — buy me a coffee.
Every start month at once
Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1985 | ||||||||||||
| 1986 | ||||||||||||
| 1987 | ||||||||||||
| 1988 | ||||||||||||
| 1989 | ||||||||||||
| 1990 | ||||||||||||
| 1991 | ||||||||||||
| 1992 | ||||||||||||
| 1993 | ||||||||||||
| 1994 | ||||||||||||
| 1995 | ||||||||||||
| 1996 | ||||||||||||
| 1997 | ||||||||||||
| 1998 | ||||||||||||
| 1999 | ||||||||||||
| 2000 | ||||||||||||
| 2001 | ||||||||||||
| 2002 | ||||||||||||
| 2003 | ||||||||||||
| 2004 | ||||||||||||
| 2005 | ||||||||||||
| 2006 | ||||||||||||
| 2007 | ||||||||||||
| 2008 | ||||||||||||
| 2009 | ||||||||||||
| 2010 | ||||||||||||
| 2011 | ||||||||||||
| 2012 | ||||||||||||
| 2013 | ||||||||||||
| 2014 | ||||||||||||
| 2015 | ||||||||||||
| 2016 | ||||||||||||
| 2017 | ||||||||||||
| 2018 | ||||||||||||
| 2019 | ||||||||||||
| 2020 | ||||||||||||
| 2021 | ||||||||||||
| 2022 | ||||||||||||
| 2023 | ||||||||||||
| 2024 | ||||||||||||
| 2025 | ||||||||||||
| 2026 |
About Baxter International
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. (Wikipedia)
It's a listed company categorised under health care and health care equipment, with a market cap of about $11.8B.
It rates Extreme Risk at 3.4/5, meaning the rated factors are poor across the board — treat any position here as speculative.
What pushes the score up: earnings quality (5.0/5) and leverage / financial (4.5/5).
Scoring well: liquidity at 1.0/5.
Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.
Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.
Risk Profile
- Annualised volatility (3yr)3/538.3
- Max drawdown from ATH4/581.3
- Beta vs S&P 5002/50.62
- Avg daily $ volume1/5164.7m
- Float % of shares outstandingnot yet researched
- Debt / equity4/51.5
- Interest coverage (EBIT / interest)5/5-1.1
- 3yr EPS volatility5/5100
- Largest customer, % of revenuenot yet researched
- Geographic revenue concentrationnot yet researched
- Board independence %not yet researched
- Share structurenot yet researched
- Litigation / audit historynot yet researched
- Sector regulatory exposure3/5elevated
Linked Assets
Same sector, or return-correlated — worth knowing what else might move if this one does.
- Abbott Laboratories ABT+45% (moderate)same category: health care, health care equipment
- Becton Dickinson BDX+39% (weak)same category: health care, health care equipment
- Medtronic MDT+38% (weak)same category: health care, health care equipment
- GE HealthCare GEHC+35% (weak)same category: health care, health care equipment
- Stryker Corporation SYK+35% (weak)same category: health care, health care equipment
- Insulet Corporation PODD+30% (weak)same category: health care, health care equipment
- Zimmer Biomet ZBH+26% (weak)same category: health care, health care equipment
- Boston Scientific BSX+26% (weak)same category: health care, health care equipment